Advertisement
YOU ARE HERE: LAT HomeCollectionsSicor Company
IN THE NEWS

Sicor Company

FEATURED ARTICLES
ARTICLES BY DATE
BUSINESS
September 1, 2001 | Bloomberg News
Sicor Inc. plans to sell 20 million shares of common stock in a secondary offering, according to regulatory documents filed Friday. The Irvine company, which makes generic drugs, plans to offer 10 million shares, and an affiliate of Chief Executive Carlo Salvi will offer the other 10 million shares. The affiliate is Rakepoll Finance NV, a subsidiary of Korbona Industries Ltd., which is owned by Salvi.
Advertisement
BUSINESS
May 1, 2001 | Dow Jones
Sicor Inc., an Irvine specialty pharmaceutical company, said its Gensia Sicor Pharmaceuticals unit received Food and Drug Administration approval to market its mesna injection to treat testicular cancer. Sicor's product has been the subject of a patent squabble between Sicor and the innovators of the product. Bristol-Myers Squibb Co. currently markets the Ifex/Mesnex injection kit for the treatment of testicular cancer, while Asta Medica markets the Mesnex injection.
BUSINESS
May 1, 2001 | Dow Jones
Sicor Inc., an Irvine specialty pharmaceutical company, said its Gensia Sicor Pharmaceuticals unit received Food and Drug Administration approval to market its mesna injection to treat testicular cancer. Sicor's product has been the subject of a patent squabble between Sicor and the innovators of the product. Bristol-Myers Squibb Co. currently markets the Ifex/Mesnex injection kit for the treatment of testicular cancer, while Asta Medica markets the Mesnex injection.
BUSINESS
February 25, 2000
Sicor Inc., an Irvine pharmaceutical company, reported fourth-quarter net income of $4.4 million, or 5 cents a share. That contrasts with a year-earlier net loss of $13.9 million, or 17 cents a share, which included a pretax charge of $3.7 million for the divestment of Gensia Automedics. Revenue advanced 50% to $65.2 million. For the year, the company posted net income of $5.7 million, or 7 cents a share, contrasted with a net loss of $24.6 million, or 31 cents a share, for the prior year.
BUSINESS
July 27, 2000
The Irvine specialty pharmaceutical company said net income for the second quarter totaled $6.9 million, or 7 cents a share. That compares with net income of $284,000 for the comparable quarter of 1999, which included charges of $1.8 million relating to the divestiture of a partial interest in Metabasis Therapeutics Inc. Revenue increased 31% to $71.8 million.
BUSINESS
July 2, 1999 | Dow Jones
Sicor Inc. said Thursday it sold a 46% stake in its Metabasis Therapeutics Inc. unit to Metabasis management, headed by Paul Laikind. Financial terms weren't disclosed. Sicor, an Irvine pharmaceutical company, said it will retain a 46% stake in Metabasis, a biopharmaceutical company, and will receive royalty payments if technologies owned by Metabasis are licensed or if products are developed and sold using those technologies.
BUSINESS
September 1, 2001 | Bloomberg News
Sicor Inc. plans to sell 20 million shares of common stock in a secondary offering, according to regulatory documents filed Friday. The Irvine company, which makes generic drugs, plans to offer 10 million shares, and an affiliate of Chief Executive Carlo Salvi will offer the other 10 million shares. The affiliate is Rakepoll Finance NV, a subsidiary of Korbona Industries Ltd., which is owned by Salvi.
BUSINESS
May 19, 2000 | Bloomberg News
AstraZeneca Plc, Europe's largest drug maker, has lost an appellate court bid to force the U.S. Food and Drug Administration to rescind its decision to allow Sicor Inc. to market a generic form of the Diprivan anesthetic. London-based AstraZeneca asked the FDA as early as 1998 not to approve generic versions of the drug, which has hypnotic properties and is used in hospital intensive care units. The company said copies of the drug could contain different preservatives and may be unsafe.
BUSINESS
July 27, 2000
The Irvine specialty pharmaceutical company said net income for the second quarter totaled $6.9 million, or 7 cents a share. That compares with net income of $284,000 for the comparable quarter of 1999, which included charges of $1.8 million relating to the divestiture of a partial interest in Metabasis Therapeutics Inc. Revenue increased 31% to $71.8 million.
BUSINESS
May 19, 2000 | Bloomberg News
AstraZeneca Plc, Europe's largest drug maker, has lost an appellate court bid to force the U.S. Food and Drug Administration to rescind its decision to allow Sicor Inc. to market a generic form of the Diprivan anesthetic. London-based AstraZeneca asked the FDA as early as 1998 not to approve generic versions of the drug, which has hypnotic properties and is used in hospital intensive care units. The company said copies of the drug could contain different preservatives and may be unsafe.
BUSINESS
February 25, 2000
Sicor Inc., an Irvine pharmaceutical company, reported fourth-quarter net income of $4.4 million, or 5 cents a share. That contrasts with a year-earlier net loss of $13.9 million, or 17 cents a share, which included a pretax charge of $3.7 million for the divestment of Gensia Automedics. Revenue advanced 50% to $65.2 million. For the year, the company posted net income of $5.7 million, or 7 cents a share, contrasted with a net loss of $24.6 million, or 31 cents a share, for the prior year.
BUSINESS
July 2, 1999 | Dow Jones
Sicor Inc. said Thursday it sold a 46% stake in its Metabasis Therapeutics Inc. unit to Metabasis management, headed by Paul Laikind. Financial terms weren't disclosed. Sicor, an Irvine pharmaceutical company, said it will retain a 46% stake in Metabasis, a biopharmaceutical company, and will receive royalty payments if technologies owned by Metabasis are licensed or if products are developed and sold using those technologies.
Los Angeles Times Articles
|